EGFR and non-small cell lung carcinoma: Platinum-based chemotherapy remains the standard of care for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations after developing EGFR-TKI resistance without EGFR T790M mutation, while the clinical benefit was limited (6).